Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,738
datasets available to search
ShareScore release 0.9.0
Dataset results
2,738 results for “multiple sclerosis”
NF-κB transcription factors RelA and c-Rel selectively control CD4+ T-cell function in multiple sclerosis and cancer [bulk_human]
GEO Series GSE239698. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
Gene expression in immortalized B-lymphocytes derived from patients with multiple sclerosis
GEO Series GSE10064. Homo sapiens. 10 samples. Type: Expression profiling by array.
Bassoon proteinopathy drives neurodegeneration in multiple sclerosis
GEO Series GSE104899. Mus musculus. 21 samples. Type: Expression profiling by high throughput sequencing; Other.
The long non-coding RNA MALAT1 contributes to the pathogenesis of multiple sclerosis through alternative splicing and backsplicing regulation
GEO Series GSE110525. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
Gene expression profiling of multiple sclerosis brain samples
GEO Series GSE135511. Homo sapiens. 50 samples. Type: Expression profiling by array.
Design of an unbiased machine learning workflow to predict Multiple Sclerosis staging from blood transcriptome
GEO Series GSE136411. Homo sapiens. 336 samples. Type: Expression profiling by array.
Gene expression and epigenetic profiling of CD34+ hematopoietic progenitor cells in multiple sclerosis patients (expression)
GEO Series GSE27688. Homo sapiens. 30 samples. Type: Expression profiling by array.
A primed immune transcriptional program is activated in oligodendroglia in multiple sclerosis [RNA-seq EZH2i]
GEO Series GSE173187. Mus musculus. 12 samples. Type: Expression profiling by high throughput sequencing.
Unstable EBV latency drives inflammation in multiple sclerosis patient derived spontaneous B cells [EBV WGS]
GEO Series GSE221624. human gammaherpesvirus 4. 9 samples. Type: Other.
Next-generation sequencing study in multiple sclerosis white matter brain lesions
GEO Series GSE138614. Homo sapiens. 98 samples. Type: Expression profiling by high throughput sequencing.
The choroid plexus in progressive multiple sclerosis presents hypoxia and secretory changes that may be related to neuroprotection
GEO Series GSE137619. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
Defective Integrator activity shapes the transcriptome of patients with multiple sclerosis: mouse model
GEO Series GSE249605. Mus musculus. 12 samples. Type: Expression profiling by high throughput sequencing.
NanoString miRNA profiling of peripheral blood sorted CD14+CD16- monocytes from amyotrophic lateral sclerosis, multiple sclerosis and healthy control subjects
GEO Series GSE39643. Homo sapiens. 24 samples. Type: Non-coding RNA profiling by array.
Unstable EBV latency drives inflammation in multiple sclerosis patient derived spontaneous B cells [Batch1]
GEO Series GSE244312. Homo sapiens. 24 samples. Type: Expression profiling by high throughput sequencing.
Antigen specificity of clonally-enriched CD8+ T cells in multiple sclerosis
GEO Series GSE291328. Homo sapiens. 36 samples. Type: Other.
Data from: "Gaming the System": a qualitative study on the price of drugs for multiple sclerosis
Objective: To describe pricing decisions, justifications, and attitudes among current and former biotech industry executives for companies that manufacture multiple sclerosis disease-modifying therapies. Methods: Four leaders in biotech who have been directly involved in multiple sclerosis disease-modifying therapy pricing and/or marketing volunteered to participate in 30-minute, semi-structured interviews conducted via telephone. An expert in qualitative methods moderated and analyzed the interviews alongside the Principal Investigator. Brief, pre-interview online surveys were also administered, to provide additional context and insight for discussion. Interviews were audio-recorded and professionally transcribed. Results: Participants consistently stated that initial price decisions were dictated by the price of existing competitors in the market. Revenue maximization and corporate growth were drivers of price escalations in the absence of continued market penetration. Lower revenue predictions outside the US also informed pricing strategies. The growing complexity and clout of drug distribution and supply channels was also cited as a contributing factor. Although decisions to raise prices were motivated by the need to attract investment for future innovation, recouping drug-specific research and development costs as a justification was not strongly endorsed as having a significant influence on pricing decisions. Conclusions: Contrary to prevailing narratives that underscore drug development costs, findings from our interviews suggest that the existing price ecosystem, overall corporate growth, international pricing disparities, and supply chain-related distortions may play a more central role to drug pricing decision.
Data from: Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia
Background. NTZ is approved in Russia for the treatment of highly active relapsing remitting multiple sclerosis and is reimbursed via federal budget program. However, no data about NTZ treatment in Russia and the effect of federal reimbursement have been performed so far. Objective. To characterize the population of patients receiving natalizumab and assess the efficacy and risk-management plan (RMP) implementation of NTZ therapy in routine clinical practice in Russia. Methods. We analyzed data for 334 patients, who received at least one infusion of NTZ. Relapse rate, MRI activity, NEDA-3 status after 2 years were assessed. Anti-JC virus antibodies status and RMP implementation were evaluated. Drop-out rate and reasons for therapy discontinuation were analyzed. Results. Patients switched to natalizumab in Russia are mainly female (63%), with median EDSS score of 3.5 and high disease activity: 93% had at least 1 relapse and 58% had both T1Gd+ and new T2 lesion an year before therapy initiation. Introduction of federal reimbursement allowed to start therapy with natalizumab for patients with less relapses. The only predictor of 6-month progression was EDSS score at the baseline of therapy (HR=2.1375, 95%CI 1.0026 – 4.5570, p=0.0492). 82% patients reached NEDA-3 at 24 month of therapy. 25% of patients discontinued NTZ for reasons: tolerability (14.5%), JCV antibody status (61%), and patient's decision (17%). RMP was implemented in only 36% patients. Conclusion. Natalizumab appeared to have high efficacy in Russian clinical practice. Federal reimbursement allowed less active patients to start natalizumab. More efforts should be done to improve RMP implementation.
Figure 1 from: Seitaridou Y, Chamova T, Kamusheva M (2024) Adherence to disease-modifying therapies among patients with multiple sclerosis in Bulgaria – A real world study. Pharmacia 71: 1-7. https://doi.org/10.3897/pharmacia.71.e117681
Figure 1 Adherence level. Legend: 0 – low adherence; 1 – moderate adherence; 2 – high adherence.
Evolution of retinal degeneration and prediction of disease activity in relapsing and progressive multiple sclerosis
<p>Retinal optical coherence tomography has been identified as biomarker for disease progression in relapsing-remitting multiple sclerosis (RRMS), while the dynamics of retinal atrophy in progressive MS are less clear. We investigated retinal layer thickness changes in RRMS, primary and secondary progressive MS (PPMS, SPMS), and their prognostic value for disease activity.</p> <p>After quality control, 2651 OCT measurements of 195 RRMS, 87 SPMS, 125 PPMS patients, and 98 controls from five German MS centers were analyzed. Peripapillary and macular retinal nerve fiber layer (pRNFL, mRNFL) thickness predicted future relapses in all MS and RRMS patients without history of optic neuritis while mRNFL and ganglion cell-inner plexiform layer (GCIPL) thickness predicted future MRI progression/activity in RRMS without history of optic neuritis (mRNFL, GCIPL) and PPMS (GCIPL). mRNFL thickness predicted future disability progression in PPMS: However, thickness change rates were subject to considerable amounts of measurement variability.</p> <p>In conclusion, retinal degeneration, most pronounced of pRNFL and GCIPL, occurs in all subtypes. Using the current state of technology, longitudinal assessments of retinal thickness may not be suitable on a single patient level.</p>
Shifts Multiple Sclerosis Lesion Segmentation Dataset Part 1
<p>This archive contains the part 1 of Shift Benchmark on Multiple Sclerosis lesion segmentation data. This dataset is provided by the Shifts Project to enable assessment of the robustness of models to distributional shift and the quality of their uncertainty estimates. This part is the MSSEG data collected in the digital repository of the OFSEP Cohort provided in the context of the MICCAI 2016 and 2021 challenges. A full description of the benchmark is available in https://arxiv.org/pdf/2206.15407. Part 2 of the data is available <a href="https://zenodo.org/record/7051692">here</a>. To find out more about the Shifts Project, please visit https://shifts.ai .</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.